Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 12/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 4/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8364667 | 0.78 | CYP2D6 (0.46) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL18534649 | 0.78 | CA1 (0.51) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL25032154 | 0.78 | CA1 (0.47) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL19015811 | 0.77 | CTSK (0.42) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL26321179 | 0.76 | CA1 (0.46) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL3096574 | 0.75 | CA1 (0.45) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL31450038 | 0.75 | CA1 (0.45) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL20334633 | 0.75 | CA1 (0.45) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL3096580 | 0.75 | CA1 (0.45) | CA1CA2CA7CTSKCYP2D6 | |
| SCHEMBL23314753 | 0.75 | CA1 (0.45) | CA1CA2CA7CTSKCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250026721-A1 | COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K | VIVIDION THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026721-A1 | COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K | KRAS, HRAS, NRAS | CA1 4347/4885CA2 3649/4885CA7 3489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.